Navigation Links
Mederi Therapeutics Announces Receipt of CE Mark for its Second Generation Secca® and Stretta® Systems
Date:11/8/2010

GREENWICH, Conn., Nov. 8, 2010 /PRNewswire/ -- Mederi Therapeutics Inc announced today that it has received a CE Mark authorizing the European distribution and use of Mederi's second generation of the Stretta and Secca Systems. The Stretta System is for treatment of gastric reflux disease, commonly known as GERD, and the Secca System is for treatment of bowel control disorder, or BCD.  These latest systems include a streamlined user interface, significant improvements in ease of use, and are smaller, lighter, and highly portable.

"Mederi is very pleased to offer the Stretta system for the treatment GERD and the Secca system for treatment of BCD. Mederi has made a substantial capital investment which has resulted in numerous improvements to these novel technologies," stated Will Rutan, CEO and President of Mederi Therapeutics. "The Secca and Stretta systems are ultra-minimally invasive technologies that bridge a significant gap that exists between conservative therapies and invasive surgical options for GERD and BCD. Numerous clinical studies have shown Stretta and Secca to be effective therapeutic options."

The second generation Stretta and Secca devices were launched at UEGW 2010, the annual congress of the United European Gastroenterology Federation, which was held in Barcelona, Spain, October 23-27. "It was exciting to witness the overwhelming response to Stretta and Secca, resulting in numerous requests to purchase Mederi products at the recent European congress. As the only endoluminal therapies for GERD and BCD, the interest and demand for these novel technologies is extremely high," added Rutan. Concurrent with the EU launch activities, Mederi has engaged and trained a worldwide distribution network to drive demand and ensure safe and proper use of Stretta and Secca.

The CE Mark and ISO 13485 certification demonstrate Mederi's steadfast commitment to safety and quality.

Additional information is available at www.mederitherapeutics.com.

ABOUT MEDERI

Mederi Therapeutics manufactures and markets innovative medical devices that deliver radiofrequency energy to treat disease states affecting the human digestive system. All Mederi therapies are outpatient, minimally invasive, and promote rapid recovery. Mederi Therapeutics is located in Greenwich, Connecticut.Contact: Sheila DoyleManager of Communications and Marketing203 930 9980
'/>"/>

SOURCE Mederi Therapeutics Inc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
2. Nektar Therapeutics Reports Third Quarter 2010 Financial Results
3. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
4. Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
5. Talecris Biotherapeutics Launches PROLASTIN®-C in Canada
6. Cell Therapeutics Awarded $977,917 in Grants Under the Therapeutic Discovery Tax Credit Program
7. Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
9. Shield Therapeutics Signs Agreement With AOP Orphan for ST10-021
10. Echo Therapeutics to Present at the LifeTech Capital 1st Annual Miami Medical Investors Conference
11. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 11, 2017  True Health, a leader in ... effort during National Breast Cancer Awareness month to ... Research recently ... that more than 10 million American women are ... BRCA1 or BRCA2 and have not had testing. These ...
(Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud ... and unique items from across the nation, this holiday-themed event will raise funds and ... the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based workplace ... Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored at ... from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located ...
Breaking Medicine News(10 mins):